Primary and secondary immune thrombocytopenia (ITP): Time for a rethink.

Blood reviews 2023 Sep

filter terms:

There are not many publications that provide a holistic view of the management of primary and secondary ITP as a whole, reflecting the similarities and differences between the two. Given the lack of major clinical trials, we believe that comprehensive reviews are much needed to guide the diagnosis and treatment of ITP today. Therefore, our review addresses the contemporary diagnosis and treatment of ITP in adult patients. With respect to primary ITP we especially focus on establishing the management of ITP based on the different and successive lines of treatment. Life-threatening situations, "bridge therapy" to surgery or invasive procedures and refractory ITP are also comprehensively reviewed here. Secondary ITP is studied according to its pathogenesis by establishing three major differential groups: Immune Thrombocytopenia due to Central Defects, Immune Thrombocytopenia due to Blocked Differentiation and Immune Thrombocytopenia due to Defective Peripheral Immune Response. Here we provide an up-to-date snapshot of the current diagnosis and treatment of ITP, including a special interest in addressing rare causes of this disease in our daily clinical practice. The target population of this review is adult patients only and the target audience is medical professionals. Copyright © 2023 Elsevier Ltd. All rights reserved.

Citation

Tomás José González-López, Drew Provan, Abelardo Bárez, Angel Bernardo-Gutiérrez, Silvia Bernat, Daniel Martínez-Carballeira, Isidro Jarque-Ramos, Inmaculada Soto, Reyes Jiménez-Bárcenas, Fernando Fernández-Fuertes. Primary and secondary immune thrombocytopenia (ITP): Time for a rethink. Blood reviews. 2023 Sep;61:101112